<DOC>
	<DOCNO>NCT00485342</DOCNO>
	<brief_summary>The aim study compare two therapeutical strategy concern combination therapy ( peginterferon alfa-2a ribavirin ) na誰ve patient chronic hepatitis C genotype 1 . `` Reference '' strategy corresponding standard care recommend French consensus conference versus `` Test '' strategy correspond adaptation strategy ribavirin dose first week accord AUC ( area curve ) ribavirin plasmatic concentration first intake ( Day 0 ) 600 mg</brief_summary>
	<brief_title>RIBAJUSTE Clinical Trial Investigating Efficacy Safety Dose Adaptation Ribavirin</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>65 year &gt; Age &gt; = 18 year Chronic hepatitis C document PCR perform within 3 month liver biopsy within 18 month serum marker fibrosis perform within 3 month inclusion FibroScan perform Naive patient physician decide initiate combination treatment chronic hepatitis C pegylated interferon alfa2a plus ribavirine Genotype VHC1 Compensated liver disease ( ChildPugh &lt; =6 ) Negative HBsAg test HIVRNA test Negative pregnancy test baseline woman age procreation efficient contraception along treatment period , 7 month discontinuation woman men Signed consent form Patient social cover Non HCV liver disease Non1 HCV genotype Organ transplant whatever organ Clinical radiological evidence liver carcinoma Severe psychiatric disorder Non compensate thyroid dysfunction Woman pregnant breastfeed Recent history epilepsy ( le 6 month ) Absolute contraindication one drug combination therapy Biological abnormality pretreatment checkup , : Neutropenia ( &lt; 1500/mm続 ) ; Haemoglobinemia ( &lt; 13 g/dL men et &lt; 12 g/dL woman ) ; Thrombopenia ( &lt; 90 000/mm続 ) ; Kidney failure ( creatinine clearance &gt; 70 ml/min ) Hypersensitivity epoetin one excipients Treatment epoetin within 2 month prior inclusion Chronic cardiac failure ( grade III IV NYHA classification ) High blood pressure unwellcontrolled ( SBP &gt; 180 mmHg inclusion spite hypertension treatment ) Previous history risk venous thrombosis Major surgery within previous 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Chronic hepatitis C , Genotype1 , Na誰f , bitherapy , Ribavirin adaptation , ribavirin AUC</keyword>
</DOC>